Introduction
Schizophrenia is a mental illness that causes considerable costs to society. 1 A recent Japanese study estimates the annual burden of disease to exceed 3.5 million yen per patient (approximately US$30,000). 2 The high costs are mainly due to the early age of onset of schizophrenia as symptoms typically begin already in young adulthood. 3 Many patients are affected during their entire lifetime with negative effects on their working ability and limited opportunities with regard to the labor market. Relapses and subsequent hospitalizations have been identified as another significant cost driver. [4] [5] [6] Hospitalizations in turn are caused by a poor adherence to antipsychotic medication. 7 In this context, it has been discussed whether the treatment with long-acting injectables (LAIs) can be a cost-effective strategy to reduce overall health care costs. 8 LAIs are intramuscularly injected every 2 weeks or 4 weeks and are usually more expensive than oral antipsychotics. On the other hand, patient adherence can be improved and, eventually, the number of relapses that lead to hospitalizations can be reduced. [9] [10] [11] [12] [13] [14] [15] [16] Accordingly, several cost-effectiveness studies demonstrated economic superiority of LAIs over oral antipsychotics. [17] [18] [19] [20] [21] [22] [23] [24] In Japan, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI) (Xeplion ® ), a once-monthly LAI antipsychotic, was approved for treatment of schizophrenia and was launched in November 2013. Paliperidone is the primary active metabolite of risperidone, which has been available since the early 1990s as an oral second-generation antipsychotic and, later, in an LAI formulation (Risperdal submit your manuscript | www.dovepress.com
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Mahlich et al Consta ® ). To our knowledge, there have been no health economic studies conducted on the use of LAIs in Japan. We therefore aim to estimate the budget impact of PLAI in the Japanese health care delivery system.
Methods
We use a budget impact model that has been published for Austria 25 and populate it with Japanese data. The model takes a 3-year horizon and is built from a health insurance perspective in that it only includes direct medical costs and abstracts from indirect costs. In schizophrenia, direct costs constitute only a small fraction of the societal burden of schizophrenia as most of the total costs are indirect productivity costs that are due to unemployment and early retirement. Included direct costs are acquisition costs of medication and hospitalization costs. Costs for outpatient treatment are included but are not related to the medication in our model. Therefore, the major drivers of the budget impact are 1) number of treated patients, 2) drug prices and respective market shares, 3) drug-specific relapse probabilities, and 4) costs and utilization of hospitals. We chose 2013 as the baseline year (t=0) that served as a benchmark for our projected economic costs and benefits.
number of patients
The number of Japanese patients with a schizophrenia diagnosis is available from publicly available sources published by the Ministry of Health, Labour and Welfare. According to these estimates, the number of patients is 713,000 or 0.56% of the total Japanese population ( Table 1) . Table 2 provides an overview of the antipsychotic medication that is available in Japan and considered in our model. The prices were taken from the official reimbursement price list. 28, 29 In the case of generic drugs, we calculated the weighted average price. Additionally, we report the lowest price of any available generic in Table 2 for information only. Due to the large number of conventionals in the Japanese market, we report only the price of haloperidol, which is taken as an estimate for all conventionals. With regard to the prescribed dosages, we assumed that patients are treated with the dosage as specified on the label. In cases where the dosage is not specified and only a range is recommended on the label, we took the mean value. For paliperidone palmitate, we were able to draw on market research data that provided us with the respective maintenance dosage distribution (IMS, unpublished data, 2014) ( Table 3 ).
Drug prices and market shares
An important building block of a budget impact model is the assumptions on future market shares of the drugs. Market shares (in terms of treatment days) were calculated by combining sales figures and dosage information according to the Japanese label. Future market shares and future prices are based on unpublished pharmaceutical market research data. 
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Budget impact of lai paliperidone palmitate use for sZ in Japan 30 While the use of generics in Japan is still low in comparison with that in other countries, it has increased substantially during the past years and is expected to rise further. 31, 32 Among the nonconventional generic drugs, the market share of generics is expected to grow from around 15% to 34% within 3 years. Note that paliperidone palmitate had been on the market in 2013 for 1 month; therefore, its market share is slightly .0 at t=0.
It can also be seen from the table that conventional antipsychotics are expected to lose market share primarily because of/on account of Quetiapine and blonanserin. The LAIs have a combined market share of roughly 1%. Probably, LAIs continue to have an image problem among patients and mental health staff despite their clinical and economic benefits. Thus, it is felt that they are primarily used as a "last resort" for the most stigmatized individuals, as argued by Waddell and Taylor. 33 Another factor that has caused a low prescription rate of LAIs is a sufficiently good estimated compliance with the oral formulation. 34 A recent analysis of Japanese claims data, however, came to the conclusion that only 25% of Japanese schizophrenia patients are adherent to their medication, while the vast majority are either under-or overadherent. 35 
Probabilities of hospitalizations and associated costs
As noted in the Introduction section, one major cost driver of schizophrenia is the direct costs of schizophrenia-caused hospitalizations. The model uses annual medication-specific probabilities for hospitalization. For risperidone, olanzapine, aripiprazole, and conventionals (haloperidol), we used the annualized relapse probabilities published by the UK National Institute for Health and Care Excellence, which were based on a systematic review. 36 Drawing on a meta-analysis by Leucht et al, 37 we assumed the rate for quetiapine to be equal to that of haloperidol. The rate for risperidone LAI (RLAI) was taken from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE) clinical trial, which compared RLAI with quetiapine.
14 For PLAI, we assumed the same rate as for RLAI. This assumption is backed by a recent long-term randomized clinical trial of PLAI, where the relapse rate of PLAI monotherapy was 11.5%. 38 The 40 blonanserin has a comparable profile as risperidone oral. For this reason, we took the same hospitalization rate as for risperidone. Table 5 summarizes the rehospitalization rates that were used in the model.
The associated costs of schizophrenia-related hospitalizations were taken from the study by Sado et al. 2 Their estimate of the total inpatient costs of schizophrenia is 602,771 million yen for 2008. Adjusting this value for price inflation using the official Japanese consumer price index 41 and dividing it by the number of schizophrenia-related hospital admissions of 187,400, 27 we estimate the costs of hospitalization to be 3.15 million yen per case (around US$26,700).
We also include costs for outpatient services, although this cost component is not related to the choice of medication in our model. The cost is based on the study of Sado et al, 42 wherein they estimate outpatient costs (without drug costs) to sum up to 80,525 million yen in the year 2008. Again, all values were adjusted using the Japanese consumer price index. There was no need to discount future costs as the 3-year interest rate in Japan is 0% according to the Japanese Ministry of Finance.
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Results and discussion
The direct medical costs of schizophrenia before and after the launch of PLAI in Japan are reported in Table 6 . Costs are categorized into drug and nondrug costs. Drug costs are expected to increase in the short run; however, due to the downward price spiral and an increase of generic drug use, the long-term drug costs are projected to fall below the baseline level. When it comes to nondrug costs, we also expect a decline in this cost component due to the shift toward more effective medical treatment opportunities that prevent relapses and hospital stays. If average values are calculated over the 3 years' time horizon, our model estimates a decrease of both drug costs and nondrug costs, which results in an overall annual cost reduction of 8,000 million yen (US$68 million). Even in the first year, cost offsets in terms of lower hospitalization rates are higher than the increase in drug costs. We therefore estimate a positive budget impact for each of the 3 years of our observation period.
sensitivity analysis
Due to a degree of uncertainty with regard to the cost per hospitalization, we ran a deterministic sensitivity analysis for this parameter. In addition to the baseline case of 3.15 million yen for the per capita cost of hospitalization, we assumed hospitalization costs to be 2.15 million yen and 4.15 million yen respectively. The results of this sensitivity analysis are reported in Table 7 . Even with lower cost of hospitalization, the results remain robust in the sense that cost offsets prevail, which lead to an overall reduction of annual direct medical costs in the range of 6,200 million yen to 9,800 million yen. 
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Budget impact of lai paliperidone palmitate use for sZ in Japan estimates for the US (US$38,100) 44 or England (£25,000 or US$37,500). 45 However, this amount is notably higher than the €7,182 (US$8,100) that was used in the Austrian model. This difference can be attributed to the differences in the length of stay in comparison to other countries. 46 While it is only 16 days in Austria, the majority of Japanese patients are hospitalized for .1 year. 47 A recent investigation of .8,000 Japanese schizophrenia patients even reported an average length of stay of 3,242 days, 48 although it has been argued that 40% of the hospitalized patients could easily be discharged sooner. 49 Despite the long hospital stays, the cost of hospitalization is low in Japan. To validate this assertion, we calculated the daily cost of schizophrenia-related hospital stays based on a claims database provided by Japan Medical Data Center Co, Ltd (JMDC). The JMDC database is an employer-based database of health insurance claims with approximately 2.5 million beneficiaries. On the basis of this analysis, mean daily costs were only 6,312 yen (US$54) per inpatient. This compares, eg, to €220 (US$250) in Germany. 18 In our view, Japanese health policy makers should address the issue of long hospital stays in combination with low daily-reimbursed costs.
Conclusion
According to our estimates, the market introduction of PLAI is associated with overall annual savings for the Japanese health care system of .8,000 million yen (US$68 million) in the baseline case. This result is robust to variations in the hospitalization costs. In our view, this estimate is rather conservative as we have not modeled any effects on the utilization of outpatient services, although there might be some additional cost savings in this sector as well. 50 We also abstracted some intangible benefits of LAIs. In a recent publication for instance, patients reported their preference for an injectable because of increased convenience when compared with oral antipsychotics. 51 As direct costs of schizophrenia constitute only 28% of the total costs for society in Japan, 2 the overall effect on the Japanese economy at large would be substantially higher. 
